Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion type Assertion NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_head.
- NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion description "[Furthermore, these data indicate that miR-7 precursor, alone or in combination with cetuximab, may be useful in therapy against CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_provenance.
- NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion evidence source_evidence_literature NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_provenance.
- NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion SIO_000772 25503932 NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_provenance.
- NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion wasDerivedFrom befree-2016 NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_provenance.
- NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_assertion wasGeneratedBy ECO_0000203 NP1247943.RA7kwlzIvcqD1aMTkt2J_0qP0ngLO4vh-EEtqWTn2PiA8130_provenance.